Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer and other solid tumors with MET dysregulation; and APL-102, an oral active, small molecule multiple tyrosine kinase inhibitor, which is in a in a Phase 1 clinical trial for cancer treatment. It also develops immuno-oncology products, such as APL-501, an anti-PD-1 antibody product candidate, which is in phase 1 clinical trial for the treatment of advanced or relapsed/refractory solid tumors; APL-502, an anti-PD-L1 antibody product candidate for the treatment of tumors; APL-810, a novel, rationally designed, ACCI recombinant vaccine for the treatment of gastrin immunogen; and APL-801, a CD40 and PD-L1 antibody product candidate for the treatment of tumors. The company was founded in 2015 and is based in Foster City, California.…
Apollomics Reports First-Half 2026 Financial Results
Apollomics (NASDAQ: APLM) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 14 employees.
The shares were at 15.53 USD on 20 November 2026, down 25.5% over 52 weeks. Its 52-week range is 10.01 USD to 28.29 USD: the price is 45.1% below the high and 55.3% above the low.
Its market capitalisation is 45.28M USD.
Apollomics reports return on equity of 343.1% and revenue down 98.8% year over year.
Its debt exceeds its cash by 995.00K USD. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health.
No upcoming events tracked.